复发或持续性卵巢癌患者腹腔内硼替佐米联合卡铂的I期药代动力学研究:一项NRG肿瘤学/妇科肿瘤组研究
该I期试验纳入33例复发卵巢癌患者,评估腹腔内硼替佐米联合卡铂(AUC 4或5)每21天一次共6周期的剂量递增方案。首个剂量水平(卡铂AUC 5、硼替佐米0.5mg/m2)出现2例剂量限制性毒性,随后卡铂降至AUC 4,硼替佐米递增至2.5mg/m2未再出现剂量限制性毒性。可测量病灶患者(n=21)总缓解率为19%(1例完全缓解,3例部分缓解)。
要点
- 腹腔内硼替佐米联合卡铂在复发卵巢癌中可行,卡铂AUC 5联合硼替佐米0.5mg/m2时出现2例剂量限制性毒性。
- 卡铂固定为AUC 4时,硼替佐米从0.5递增至2.5mg/m2未出现剂量限制性毒性。
- 可测量病灶患者(n=21)总缓解率为19%(1例完全缓解,3例部分缓解)。
核心结论
- 腹腔内给予硼替佐米联合卡铂这一新组合在经重度治疗的卵巢癌患者I期试验中可行,并显示出有前景的活性;应进一步评估该腹腔内联合方案。
研究设计与样本
- I期临床试验,纳入33例复发卵巢癌女性,其中32例可评估安全性。
- 腹腔内硼替佐米剂量递增联合腹腔内卡铂(AUC 4或5),每21天一次,共6周期;第1周期评估两药药代动力学。
主要发现
- 首个剂量水平(卡铂AUC 5、硼替佐米0.5mg/m2)有2例患者出现剂量限制性毒性,随后剂量水平卡铂降至AUC 4。
- 卡铂剂量固定为AUC 4时,硼替佐米从0.5递增至2.5mg/m2未出现剂量限制性毒性。
- 3/4级相关毒性包括腹痛、恶心、呕吐和腹泻,均不常见。
- 可测量病灶患者(n=21)总缓解率为19%(1例完全缓解,3例部分缓解)。
- 腹膜液和血浆中Cmax与AUC随剂量线性增加,腹腔相对外周血浆的暴露比有利。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Intraperitoneal (IP) therapy improves survival compared to intravenous (IV) treatment for women with newly diagnosed, optimally cytoreduced, ovarian cancer. However, the role of IP therapy in recurrent disease is unknown. Preclinical data demonstrated IP administration of the proteasome inhibitor, bortezomib prior to IP carboplatin increased tumor platinum accumulation resulting in synergistic cytotoxicity. We conducted this phase I trial of IP bortezomib and carboplatin in women with recurrent disease. METHODS: Women with recurrent ovarian cancer were treated with escalating doses of IP bortezomib - in combination with IP carboplatin (AUC 4 or 5) every 21days for 6cycles. Pharmacokinetics of both agents were evaluated in cycle 1. RESULTS: Thirty-three women participated; 32 were evaluable for safety. Two patients experienced dose-limiting toxicity (DLT) at the first dose level (carboplatin AUC 5, bortezomib 0.5mg/m2), prompting carboplatin reduction to AUC 4 for subsequent dose levels. With carboplatin dose fixed at AUC 4, bortezomib was escalated from 0.5 to 2.5mg/m2 without DLT. Grade 3/4 related toxicities included abdominal pain, nausea, vomiting, and diarrhea which were infrequent. The overall response rate in patients with measurable disease (n=21) was 19% (1 complete, 3 partial). Cmax and AUC in peritoneal fluid and plasma increased linearly with dose, with a favorable exposure ratio of the peritoneal cavity relative to peripheral blood plasma. CONCLUSION: IP administration of this novel combination was feasible and showed promising activity in this phase I trial of heavily pre-treated women with ovarian cancer. Further evaluation of this IP combination should be conducted.
引用
- Jandial DA, Brady WE, Howell SB, et al. A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017. PMID: 28341300. doi:10.1016/j.ygyno.2017.03.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。